News from INC Research, Y-Prime and Ariana – People on the move
INC Research has appointed former Quintiles exec Neil Ferguson as its new executive VP of business development.
In his new role, Ferguson will help recently appointed CEO Jamie Macdonald to implement the firms’ latest growth plans.
Previously, he was VP and head of commercial sales for Quintiles North America.
Also moving on from Quintiles is former associate director of integrated site services Joanne Mashburn, who will become VP of quality assurance (QA) for Clinical Research Advantage (CRA).
In her new role for the clinical service provider, she will take charge of the overall planning and implementation of QA initiatives within CRA's 34 clinical research sites in Arizona, California, Colorado, Indiana, Iowa, Nebraska, and Nevada.
Mark Hanley, CEO said: "Now more than ever pharmaceutical companies and contract research organisations (CROs) want to conduct clinical trials that are cost-effective, efficient, and maintain the highest standards for patient safety.
“Joanne brings a wealth of knowledge and experience that will help CRA to continue to be the market leader for high quality clinical trials."
eClinical consultant Y-Prime Technologies has drafted in Jeanette Greef as a senior business analyst to help drive its recently expanded operations in Europe.
The Pennsylvania, US, based firm says Greef will help client penetration in the region.
Prior to Y-Prime, she worked for Medimmune, and also served as director of regulatory and clinical services in Europe and India for Liquent.
Ariana Pharma has named Mariana Kuras as its new chief technology officer.
Kuras takes the role after an eight-year career with Biosystems International, where she was director of research.
For Ariana – who provide a qualitative analysis of clinical datasets – she will work specifically with biomarkers.
Mohammad Afshar, president and CEO said: “Demand for our biomarker activity has continued to increase dramatically as a result of the drive in life science industries to personalised medicine.
“Mariana’s unique hands-on experience of both computational and experimental aspects of biomarker development will be a key asset to Ariana.”
Allison Jeynes-Ellis will become a board member for bioscience and healthcare facility BioCity Scotland.
Currently a freelance oncology consultant, Jeynes-Ellis’ 20-year-career in the field includes exec roles at Bristol Myers Squibb and Wyeth.
Chairman Louis Nisbet said: "Her extensive experience with the pharmaceutical and biotechnology industries, coupled with her government and NHS relationships will be immensely valuable.”
